Topical application of amelogenin extracellular matrix protein in non-healing venous ulcers [¯yileşmeyen venöz ülserlerde topikal amelogenin ekstrasellüler matriks protein uygulamasi]

Background and Design: Treatment of chronic venous ulcers of the lower extremity is still an important difficulty. The principal treatment of these ulcers includes compression therapy, local wound care and surgery. Unresponsiveness to these standard treatments is a frequent situation with negative effects on life quality and reductions in personal productivity. Therefore, there is a need for new applications to increase the effectiveness of treatment in treatment-resistant cases. In the present study, we retrospectively evaluated the results of topical application of amelogenin extracellular matrix protein in resistant venous ulcers. Materials and Methods: We analyzed the records of patients with treatment-resistant venous ulceration who were treated with amelogenin extracellular matrix protein between June 2011 and December 2012. Results: 26 patients (21 male and 5 female) with a total number of 28 ulcers (24 patients with 1 ulcer, 2 patients with two ulcers) were evaluated. The patients were treated with topically applied amelogenin extracellular matrix protein and regional four bandage compression. Bandages were changed weekly. Each cure continued for six weeks. In fourteen patients (15 ulcers), we observed a complete healing by the end of the first cure. In another twelve cases (13 ulcers), the same period resulted with a reduction in wound diameter. We continued to the second cure for these patients. By the end of the second cure, complete healing was achieved in five cases (6 ulcers). Conclusion: Topical application of amelogenin extracellular matrix protein may be considered as an effective therapeutic choice for refractory venous ulcers. (Turkderm 2014; 48: 237-41).